Search clinical trials for: Peginterferon alfa ribavirin

Total 3520 results

Ruijin Hospital

Recruiting

Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients

Chronic Hepatitis

China
Tongji Hospital
Xiamen Amoytop Biotech Co., Ltd.

Unknown

A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

Hepatitis B, Chronic

China
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Chronic Hepatitis C (CHC)

Japan
Biolex Therapeutics, Inc.

Completed

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV (SELECT-2)

Hepatitis C, Chronic

United States, Bulgaria, Puerto Rico, Romania
USDA, Western Human Nutrition Research Center
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Assessing the Quality of Breast Milk

Micronutrient Deficiency

Bangladesh
University Hospital, Bordeaux
Schering-Plough

Completed

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) (EADO)

Melanoma | Neoplasm Metastasis

France
Bristol-Myers Squibb

Completed

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Hepatitis C

France, United Kingdom, Spain, United States, Italy, Puerto Rico, Greece
Merck Sharp & Dohme LLC

Completed

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
Vertex Pharmaceuticals Incorporated

Terminated

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Hepatitis C

Canada, United States
University Hospital, Basel, Switzerland

Completed

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Hepatitis C

Switzerland
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Bulgaria
Ruijin Hospital

Unknown

Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients

Chronic Hepatitis B

China
Gangnam Severance Hospital
Roche Pharma AG

Unknown

HBsAg Related Response Guided Therapy (S-RGT)

Hepatitis B, Chronic

Korea, Republic of
Chang Gung Memorial Hospital
Merck Sharp & Dohme LLC

Unknown

36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8

Hepatitis C Infection

Taiwan
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Sun Yat-sen University

Unknown

Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss

Hepatitis B

China
Romark Laboratories L.C.

Completed

4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

Chronic Hepatitis C

Egypt
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Indivior Inc.
AESCA Pharma GmbH

Terminated

Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)

Hepatitis C, Chronic
Hanmi Pharmaceutical Company Limited

Unknown

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Chronic Hepatitis C Virus Genotype I

Mexico
Hanmi Pharmaceutical Company Limited

Completed

Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects

Healthy

Netherlands
Hepatera Ltd.

Completed

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Chronic Hepatitis D Infection
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

China
Novartis Pharmaceuticals
Human Genome Sciences Inc.

Terminated

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Chronic Hepatitis B

Taiwan, Poland, China, Hong Kong, Thailand
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Hepatitis D, Chronic

Turkey
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Hepatitis C, Chronic

United States, Puerto Rico
Sheba Medical Center

Unknown

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Chronic Hepatitis C
Bristol-Myers Squibb

Completed

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (Hallmark QUAD)

Hepatitis C Virus

United States, Germany, Italy, Korea, Republic of, Sweden, Russian Federation, Canada, France, Argentina, Switzerland, Denmark, Taiwan, Netherlands, Spain, Mexico
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Charite University, Berlin, Germany

Completed

Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients (CIPPAD)

Depression

Germany
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
University of Central Florida
Virtually Better, Inc.

Completed

Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety

Anxiety Disorders

United States
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
National Institute of Diabetes and Digestive and...
University of Pittsburgh; National Center for Research Resources (NCRR)

Completed

Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (HBRN)

Hepatitis B

United States, Canada
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Chronic Hepatitis C (CHC)
National Cancer Institute (NCI)

Terminated

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
University Hospital, Limoges
Hoffmann-La Roche

Completed

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM (CINAM)

Chronic Hepatitis C

France
Novartis

Terminated

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

Hepatitis B

United States
National Taiwan University Hospital
PharmaEssentia

Recruiting

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Chronic Hepatitis B Virus Infection

Taiwan
Henan Provincial People's Hospital

Unknown

A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs

Chronic Hepatitis B

China
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC

Terminated

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Myelofibrosis

United States
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection

Chronic Hepatitis b

China
University of Michigan Rogel Cancer Center

Terminated

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States
Fundación de Investigación Biomédica - Hospital...
Haematology Service,

Unknown

Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)

Multiple Mieloma

Spain

3

Subscribe